Voyager Therapeutics announces data from SAD trial of VY7523
Voyager Therapeutics (VYGR) announced positive topline data from the Company’s single ascending dose, SAD, trial of VY7523, an investigational ...
Voyager reports promising data for early stage trial in Alzheimer’s disease treatment
Voyager Therapeutics (VYGR) said on Monday that the company provided positive topline data from its early stage trial of VY7523, an antibody to selectively inhibit the spread of pathological tau in ...
Nasdaq3d
Voyager Therapeutics Reports Positive Topline Data for VY7523 in Alzheimer’s Disease Trials
Voyager Therapeutics announced positive results from the single ascending dose (SAD) trial of its investigational anti-tau antibody, VY7523, which demonstrates safety, tolerability, and dose ...
Nasdaq3d
Voyager Therapeutics Reports Positive Data From Single Ascending Dose Study Of VY7523
(RTTNews) - Voyager Therapeutics, Inc. (VYGR) Monday announced positive topline data from its single ascending dose (SAD) study of VY7523 developed for the treatment of Alzheimers disease (AD).
Investing3d
Voyager reports positive early data in Alzheimer’s study
VY7523 is designed as an intravenous anti-tau antibody to selectively inhibit the spread of pathological tau, a protein linked to disease progression and cognitive decline in Alzheimer’s.
Business Insider1mon
Positive Outlook for Voyager Therapeutics Driven by Promising CNS Gene Therapies and Innovative TRACER Platform
The company is advancing multiple programs, such as VY7523 and VY1706, which are focused on addressing neurodegenerative diseases like Alzheimer’s and ALS. These programs are nearing important ...
Investing3d
Voyager reports positive early data in Alzheimer's study
VY7523 is designed as an intravenous anti-tau antibody to selectively inhibit the spread of pathological tau, a protein linked to disease progression and cognitive decline in Alzheimer's.